Searchable abstracts of presentations at key conferences in endocrinology

ea0059s3.2 | Horizons in adrenal medicine | SFEBES2018

Urine steroid metabolomics in adrenal incidentaloma

Bancos Irina

Adrenal masses are discovered in 5% of abdominal imaging scans and the diagnostic work-up has to address two major questions: does the adrenal mass overproduce hormones and, most important to the patient, does the adrenal tumour represent cancer? The reported incidence of adrenocortical carcinoma varies in reported series from 2 to 11%. However, the accuracy of currently available imaging tests to diagnose malignancy is poor. Urine steroid metabolomics is a combination of ster...

ea0056gp20 | Adrenal Case reports | ECE2018

Cushing’s syndrome revealing carney complex due to novel PRKAR1A mutation

Zhang Catherine D , Bancos Irina

Introduction: Carney complex (CNC) is a rare multiple neoplasia syndrome characterized by pigmented lesions of the skin and mucosa in association with various endocrine and non-endocrine tumors. The disease can be inherited in an autosomal-dominant fashion or occur sporadically due to novel mutations in the PRKAR1A gene. Primary pigmented nodular adrenocortical disease (PPNAD) is a common endocrine manifestation of CNC.Case description: A 20-year-old wom...

ea0073aep546 | Pituitary and Neuroendocrinology | ECE2021

A double-blind, randomized, placebo-controlled trial of SPI-62 safety and efficacy for the treatment of Cushing’s syndrome

Fleseriu Maria , Bancos Irina , Katz David

11β-hydroxysteroid dehydrogenase type 1 (HSD-1) controls the intracellular cortisol pool that has access to cytosolic glucocorticoid and mineralocorticoid receptors. HSD-1 activity is elevated in patients with Cushing’s syndrome (CS).1 Patients with CS and constitutionally low HSD-1 activity showed no hypercortisolism-related symptoms despite very high 24-hour urine free cortisol.2, 3 A recent pilot trial of a HSD-1 inhibitor in patients with classical or mild CS sho...

ea0099ep1098 | Adrenal and Cardiovascular Endocrinology | ECE2024

Testosterone producing adrenal cortical carcinoma in a post-menopausal woman

Moazzami Mitra , Lyden Melanie , Bancos Irina

Introduction: In post-menopausal women, the differential diagnosis of hirsutism caused by testosterone excess includes ovarian and adrenal sources. Bilateral ovarian hyperthecosis is a common cause of testosterone excess in post-menopausal women and the diagnosis is confirmed by histopathological examination of the ovaries. Adrenal tumors causing testosterone excess is exceedingly rare. In fact, most causes of hirsutism secondary to adrenal tumors is due to dehydroepiandroster...

ea0032p862 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Clinical diagnostic implications of sequential pattern of dynamic MRI for pituitary microadenoma

Guo Qinghua , Erickson Dana , Young William , Bancos Irina , Erickson Bradley

Objective: We examined whether sequential enhancement patterns of pituitary microadenomas on dynamic MRI correlates with different subtypes of pituitary tumors.Materials and methods: Patients with pituitary microadenomas imaged via dynamic MRI between years 2000 and 2012 were included. The intensity of the adenoma and of normal gland at each time point in the dynamic sequence was measured by drawing a region of interest (ROI) on both the normal pituitary...

ea0090p14 | Adrenal and Cardiovascular Endocrinology | ECE2023

Opioid Use and Adrenal Insufficiency in Olmsted County, MN, USA: A Population-Based Study

Moazzami Mitra , J. Achenbach Sara , J. (Beth) Atkinson Elizabeth , Bancos Irina

Background: Chronic opioid use may lead to adrenal insufficiency (AI) due to suppression of the hypothalamic-pituitary-adrenal axis. We aimed to determine incidence of AI and mortality in patients treated with chronic opioid therapy in a standardized geographically well-defined population.Methods: In this population-based cohort study we assessed the standardized incidence rate of first time met chronic opioid use and adrenal insufficiency in adult resid...

ea0063p18 | Adrenal and Neuroendocrine Tumours 1 | ECE2019

Evaluating the applicability of urinary miR-483-5p as a non-invasive marker in adrenocortical cancer patients

Decmann Abel , Bancos Irina , Thomas Melinda A , Turai Peter , Perge Pal , Toth Miklos , Patocs Attila , Igaz Peter

Introduction: Minimally invasive blood-borne circulating microRNAs might be used for the preoperative differentiation of adrenocortical carcinoma (ACC) and adrenocortical adenoma (ACA). Circulating hsa-miR-483-5p is so far the best microRNA biomarker of ACC. To the best of our knowledge, there have been no studies concerning the potential applicability of urinary has-miR-483-5p as a non-invasive biomarker of ACC and its correlation with plasma hsa-miR-483...

ea0037ep1145 | Endocrine tumours | ECE2015

Mitotane treatment for metastatic Leydig cell tumour

Chortis Vasileios , Johal Nicholas , Cullen Michael , Bancos Irina , Guest Peter , Porfiri Emilio , Arlt Wiebke

Introduction: Testicular leydig cell tumours (LCTs) are rare stromal tumors often associated with androgen excess. Metastatic malignant LCTs typically show resistance to radiotherapy and cytotoxic chemotherapy, calling for alternative management options. Here we describe our experience with treatment of two patients with metastatic LCTs with the adrenolytic drug Mitotane.Patients/methods: Case 1: A 51-year-old patient presented with a 6 month hi...

ea0099p424 | Adrenal and Cardiovascular Endocrinology | ECE2024

Diagnostic performance of dehydroepiandrosterone sulfate in predicting adrenal insufficiency

Han Ashley , Achenbach Sara J , Atkinson Elizabeth J (Beth) , Bancos Irina

Background: Diagnosing adrenal insufficiency (AI) often requires complex multi-step testing which can be expensive and time consuming. In this study, we evaluated the diagnostic performance of baseline dehydroepiandrosterone sulfate (DHEAS) level in identifying patients with AI.Methods: A single-center retrospective cohort study was performed of patients who underwent Cosyntropin stimulation testing (CST) between 2005 and 2023 and had a baseline DHEAS le...

ea0044p130 | Neoplasia, cancer and late effects | SFEBES2016

Diagnostic performance of adrenal imaging in a high risk population for adrenal malignancy

Delivanis Danae , Nathan Mark , Atwell Thomas , Eiken Patrick , Schmit Grant , Natt Neena , Erickson Dana , Maraka Spyridoula , Young William , Bancos Irina

Objective: There is limited evidence on the diagnostic accuracy of imaging tests in patients at high risk for adrenal malignancy. Our objective was to determine the performance of computed tomography (CT) and 18FDG-PET/CT imaging in diagnosing a malignant adrenal mass in a high risk population of patients referred for CT-guided adrenal biopsy.Methods: We retrospectively reviewed the medical records of 378 patients who had percutaneous adrenal ...